Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Soleno Therapeutics, Inc. - Common Stock
(NQ:
SLNO
)
45.90
+0.68 (+1.50%)
Streaming Delayed Price
Updated: 10:41 AM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Soleno Therapeutics, Inc. - Common Stock
SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
September 25, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
September 24, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
↗
September 24, 2025
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.
Via
Benzinga
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
↗
August 15, 2025
Via
Stocktwits
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Soleno Therapeutics's Earnings: A Preview
↗
August 05, 2025
Via
Benzinga
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
↗
September 24, 2025
The companies are working on treatments for a rare, genetic disease that can cause excessive hunger.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
September 24, 2025
Via
Benzinga
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
September 20, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
September 18, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
September 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
September 11, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Soleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
September 10, 2025
From
Gibbs Mura
Via
Business Wire
SLNO Investors Have Opportunity to Join Soleno Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
September 10, 2025
From
The Schall Law Firm
Via
Business Wire
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside
↗
September 10, 2025
Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.
Via
Stocktwits
Topics
Death
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
September 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
September 09, 2025
Via
Benzinga
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
September 08, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
September 07, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
September 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Fortinet, Roblox, Soleno, and Simulations Plus and Encourages Investors to Contact the Firm
September 04, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
September 02, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
August 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm
August 26, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO
August 25, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
August 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe
↗
August 15, 2025
Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal.
Via
Benzinga
Soleno (SLNO) Q2 Revenue Jumps 30%
↗
August 06, 2025
Via
The Motley Fool
Soleno Therapeutics Inc (NASDAQ:SLNO) Reports Q2 2025 Earnings Beat with Strong VYKAT™ XR Launch Performance
↗
August 06, 2025
Soleno Therapeutics (SLNO) reported Q2 2025 revenue of $32.66M, beating estimates by 27.4%, with a narrower EPS loss. Stock rose 1.23% post-earnings amid strong VYKAT™ XR launch.
Via
Chartmill
Topics
Earnings
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
↗
July 10, 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Via
Investor's Business Daily
Topics
Intellectual Property
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
